Imagine a future where the global incident cases of liver cancer almost doubles, rising from 870 000 cases in 2022 to over ...

Researchers warn that the public, policy makers and even clinicians are not aware of the growing problem of liver cancer.

There's been plenty of buzz about this class of drug, following publication of a high-profile trial this year. How much do we ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type 2 diabetes.

Researchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Powerful new medications such as Ozempic and Mounjaro, known as GLP-1 drugs are helping to win the war against obesity in ...

In a study on people with obesity and asthma, researchers saw “significant” improvements in the asthma scores of people who ...

Once scorned as a cosmetic lifestyle disfigurement, obesity today is recognised as a chronic and progressive disease. From ...

The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?

Tom Nolan reviews this week’s research Cannabinol—aka CBD—is a modern day tonic for almost any ailment, available in all good vape shops and petrol stations. In 2023, the Food Standards Agency cut the ...

Low doses of the injectable weight-loss medication semaglutide may improve symptoms of a hard-to-treat type of heart failure.